The SAGITTARIUS Trial: Precision Adjuvant Therapy
Spanish institutions are at the forefront of the SAGITTARIUS trial (NCT06490536), which is reaching its primary data completion in March 2026.
The Science: This Phase III trial uses liquid biopsy to detect Minimal Residual Disease (MRD) in Stage II and III colon cancer patients post-surgery.
Clinical Shift: Instead of treating all patients with standard chemotherapy, clinicians at centers like Hospital del Mar (Barcelona) and INCLIVA (Valencia) use the molecular profile of the circulating tumor DNA (ctDNA) to assign personalized therapies (e.g., targeted drugs or immunotherapy).
Patient Outcome: The trial aims to prove that guiding therapy via liquid biopsy significantly reduces recurrence rates and spares low-risk patients from unnecessary chemotherapy toxicity.